Rabeprazole capsules 20mg №14

Composition:

1 capsule contains:

Active substance:

rabeprazole pellets - 118 mg, 236 mg

in terms of rabeprazole sodium - 10 mg, 20 mg

[Pellet core: Rabeprazole sodium - 10.00 mg, 20.00 mg, sugar semolina (sucrose, starch syrup) - 71.47 mg, 142.94 mg, sodium carbonate - 1.65 mg, 3.30 mg, talc - 1.77 mg, 3.54 mg, titanium dioxide - 0.83 mg, 1.66 mg, hypromellose (hydroxymethylcellulose) - 14.75 mg, 29.50 mg;

shell pellets: hypromellose phthalate (hydroxypropylmethyl cellulose phthalate) - 15.93 mg, 31.86 mg, cetyl alcohol - 1.60 mg, 3.20 mg].

Excipients:

Solid gelatin capsules No. 3 (dosage 10 mg):

body: titanium dioxide - 2.0%, gelatin - up to 100%;

cap: dye azorubine (dye Karmazin) - 0.6619%, indigo carmine - 0.0286%, titanium dioxide - 0.6666%, gelatin - up to 100%.

Solid gelatin capsules No. 1 (dosage 20 mg):

body: titanium dioxide - 1.0%, iron oxide yellow - 0.192% gelatin - up to 100%;

cap: ferrous oxide black - 0.53%, ferric oxide red - 0.93%, titanium dioxide - 0.3333%, ferric oxide yellow - 0.20%, gelatin - up to 100%.

Description:

Solid gelatin capsules No. 3, white body with a lid of dark red color (for dosage 10 mg); hard gelatin capsules No. 1, yellow body with brown cap (for dosage 20 mg).

The contents of the capsules are spherical pellets from almost white to white with a creamy or yellowish shade of color.

Pharmacodynamics:

Rabeprazole belongs to the class of antisecretory substances, benzimidazole derivatives. Inhibits the secretion of gastric juice by specific inhibition of H + / K + -ATP-ase on the secretory surface of the parietal cells of the stomach. Blocks the final stage of secretion of hydrochloric acid, reducing the content of basal and stimulated secretion, regardless of the nature of the stimulus.

Possessing high lipophilicity, it easily penetrates into the parietal cells of the stomach, concentrates in them, exerting a cytoprotective effect and increasing the secretion of bicarbonate.

Antisecretory effect after oral administration of 20 mg of rabeprazole, occurs within 1 hour and reaches a maximum after 2-4 hours; Inhibition of basal and food-stimulated acid secretion 23 hours after the first dose is 62 and 82%, respectively, and lasts up to 48 hours. When you stop taking secretory activity is restored within 1-2 days.

During the first 2-8 weeks of treatment with rabeprazole, the concentration of gastrin in the blood plasma increases (which is a reflection of the inhibitory effect on the secretion of hydrochloric acid) and returns to baseline levels 1-2 weeks after it is canceled.

Rabeprazole does not have anticholinergic properties, does not affect the central nervous system (CNS), cardiovascular and respiratory systems.

In the presence of rabeprazole, steady changes in the morphological structure of enterochromine-like cells, in the severity of gastritis, in the frequency of atrophic gastritis, intestinal metaplasia, or the spread of Helicobacter pylori infection.

Indications:

- Peptic ulcer of the stomach in the acute stage and ulcer of the anastomosis;

- Duodenal ulcer in the acute stage;

- erosive and ulcerative gastroesophageal reflux disease (GERD) - adults and children from 12 years or reflux esophagitis;

- supportive therapy of gastroesophageal reflux disease;

- non-erosive gastroesophageal reflux disease;

- Zollinger-Ellison syndrome and other conditions characterized by pathological hypersecretion;

- in combination with appropriate antibiotic therapy for the eradication of Helicobacter pylori in patients with peptic ulcer.

Contraindications:

- Hypersensitivity to rabeprazole, substituted benzimidazoles or to auxiliary components of the drug;

- deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose deficiency;

- pregnancy;

- breastfeeding period;

- children's age up to 18 years, with the exception of GERD (children's age up to 12 years).

Carefully:

- Severe renal failure;

- severe liver failure.

Pregnancy and lactation:

There are no data on the safety of using rabeprazole during pregnancy.

Reproductive studies in rats and rabbits showed no signs of impaired fertility or fetal developmental defects caused by rabeprazole; however, in rats in small quantities, the drug penetrates the placental barrier. Rabeprazole should not be used during pregnancy.

It is not known whether rabeprazole is excreted in breast milk.Relevant studies on the use of the drug during the breastfeeding period were not conducted. However, rabeprazole is found in the milk of lactating rats, and therefore rabeprazole should not be used during breastfeeding.

Dosage and administration:

The capsules of Rabeprazole-SZ should be swallowed whole. It was established that neither the time of day nor food intake affect the activity of rabeprazole.

In case of peptic ulcer of the stomach in the acute stage and ulcer of the anastomosis, it is recommended to take orally 10 mg or 20 mg once a day. Usually, the cure comes after 6 weeks of therapy, but in some cases the duration of treatment may be increased by another 6 weeks.

In case of peptic ulcer of the duodenum in the acute stage it is recommended to take orally 20 mg once a day. In some cases, the therapeutic effect occurs when taking 10 mg once a day. The duration of treatment is from 2 to 4 weeks. If necessary, the duration of treatment can be increased by another 4 weeks.

When treating erosive gastroesophageal reflux disease (GERD) or reflux esophagitis, it is recommended to take orally 10 mg or 20 mg once a day. The duration of treatment is from 4 to 8 weeks. If necessary, the duration of treatment can be increased by another 8 weeks.

With the maintenance therapy of gastroesophageal reflux disease (GERD), it is recommended to take orally 10 mg or 20 mg once a day. The duration of treatment depends on the condition of the patient.

For non-erosive gastroesophageal reflux disease (NERD) without esophagitis, it is recommended to take orally 10 mg or 20 mg once a day.

If after four weeks of treatment the symptoms do not disappear, additional research should be carried out on the patient. After stopping the symptoms to prevent their subsequent occurrence, the drug should be taken orally at a dose of 10 mg once a day as required.

For the treatment of Zollinger-Ellison syndrome and other conditions characterized by pathological hypersecretion, the dose is selected individually. The initial dose is 60 mg per day, then the dose is increased and the drug is administered in a dose of up to 100 mg per day with a single dose or 60 mg twice a day. For some patients, fractional dosing of the drug is preferred. Treatment should continue as needed. In some patients with Zollinger-Ellison syndrome, the duration of treatment with rabeprazole was up to one year.

For eradication of Helicobacter pylori, it is recommended to take orally 20 mg 2 times a day according to a specific regimen with appropriate combinations of antibiotics. The duration of treatment is 7 days.

Patients with renal and hepatic failure

Dose adjustment in patients with renal insufficiency is not required.

In patients with mild to moderate hepatic insufficiency, the concentration of rabeprazole in the blood is usually higher than in healthy volunteers.

In the appointment of the drug Rabeprazole-SZ patients with severe severity of liver failure, caution should be exercised.

Dose adjustment is not required.

Children

The safety and efficacy of rabeprazole 20 mg for short-term (up to 8 weeks) treatment of GERD in children aged 12 years and more is confirmed by extrapolating the results of adequate and well-controlled studies that support the effectiveness of rabeprazole for adults and safety and pharmacokinetics for children of children. The recommended dose for children aged 12 years or more is 20 mg 1 time per day for up to 8 weeks.

The safety and efficacy of rabeprazole for the treatment of GERD in children under the age of 12 years has not been established. The safety and efficacy of rabeprazole for use in other indications has not been established for pediatric patients.

Side effects:

During clinical studies, the following adverse reactions were noted when taking rabeprazole: headache, dizziness, asthenia, abdominal pain, diarrhea, flatulence, dry mouth, rash.

Undesirable reactions are systematized in accordance with the WHO classification:

Very often (> 1/10);

Often (> 1/100, <1/10);

Infrequently (> 1/1000, <1/100);

Seldom (> 1/10000, <1/1000);

Very rarely (<1/10000);

Frequency unknown (cannot be determined from available data).

On the part of the immune system: rarely - acute systemic allergic reactions (including swelling of the face, hypotension, shortness of breath).

From the side of blood and lymphatic system: rarely - thrombocytopenia, neutropenia, leukopenia.

Metabolism and nutrition: rarely - anorexia; frequency is unknown - hyponatremia, hypomagnesemia.

On the part of the nervous system: often - insomnia, headache, dizziness; infrequently - drowsiness, nervousness; rarely, depression; frequency unknown confusion.

On the part of the organ of vision: rarely - visual impairment.

On the part of the vessels: the frequency is unknown - peripheral edema.

On the part of the respiratory system: often - cough, pharyngitis, rhinitis; infrequently - sinusitis, bronchitis.

On the part of the digestive system: often - abdominal pain, diarrhea, flatulence, nausea, vomiting, constipation; infrequently - dyspepsia , belching, dry mouth; rarely - stomatitis, gastritis, taste disorder.

On the part of the hepatobiliary system: rarely - hepatitis, jaundice, hepatic encephalopathy.

On the part of the kidneys and urinary tract: infrequently - urinary tract infection; rarely interstitial nephritis.

From the skin and subcutaneous tissues: rarely - bullous rash, urticaria; very rarely - erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome.

On the part of the musculoskeletal system: often - back pain; infrequently - myalgia, arthralgia, leg muscle cramps, fractures of the hip, wrist or spine.

Reproductive system: frequency unknown - gynecomastia.

From the laboratory and instrumental studies: rarely - increased activity of "liver" transaminases,weight gain.

Other: often - infections.

Overdose:

Symptoms

Data on intentional or accidental overdose is minimal.

Treatment

The specific antidote for rabeprazole is unknown. Rabeprazole binds well to plasma proteins and is therefore poorly excreted during dialysis. In case of overdose, symptomatic and supportive treatment is necessary.

Special instructions:

The patient's response to rabeprazole therapy does not exclude the presence of malignant tumors in the stomach.

The capsules of Rabeprazole-SZ should be swallowed whole. It was established that neither the time of day nor food intake affect the activity of rabeprazole.

In a special study in patients with mild or moderate liver dysfunction, there was no significant difference in the incidence of side effects of Rabeprazole-SZ from that of healthy individuals matched by gender and age, but despite this, caution is advised when first administering Rabeprazol- NW patients with severely impaired liver function.

Patients with impaired renal or hepatic function do not need to adjust the dose of Rabeprazole-SZ. AUC of rabeprazole in patients with severe hepatic impairment is approximately two times higher than in healthy patients.

Hypomagneemia

In the treatment of PPI for at least 3 months, there have been rare cases of symptomatic or asymptomatic hypomagnesemia. In most cases, these messages were received one year after the treatment.Serious side effects were tetany, arrhythmia, and seizures. Most patients required treatment for hypomagnesemia, including Magnesium replacement and discontinuation of IPP therapy. In patients who will receive long-term treatment or who are taking an IPP with drugs such as Digoxin or drugs that can cause hypomagnesemia (for example, diuretics), medical professionals should monitor magnesium content before starting an IPP treatment and during treatment.

Fractures

IPP therapy can increase the risk of osteoporosis-related fractures of the hip, wrist, or spine. The risk of fractures was increased in patients who received high doses of IPP for a long time (a year or more).

The simultaneous use of rabeprazole with Methotrexate

According to the literature, taking IPP with methotrexate at the same time (especially in high doses) can lead to an increase in the concentration of methotrexate and / or its metabolite hydroxymetotrexate and an increase in the half-life, which can lead to toxicity of methotrexate. If necessary, the use of high doses of methotrexate, may be considered the possibility of a temporary cessation of therapy with IPP.

Infections caused by Salmonella, Campylobacter and Clostridium difficile

IPP therapy can increase the risk of gastrointestinal infections, such as infections caused by Salmonella, Campylobacter and Clostridium difficile.

Impact on the ability to drive trans. Wed and fur .:

Based on the features of the pharmacodynamics of rabeprazole and its profile of undesirable effects, it is unlikely that Rabeprazole-SZ affects the ability to drive vehicles and control mechanisms.However, in the event of drowsiness, these activities should be avoided.

Form release / dosage:

Enteric capsules, 10 mg and 20 mg.

Packaging:

10 or 14 capsules in a blister packaging.

On 30, 60 or 100 capsules in a polymer jar or in a polymer vial.

Each jar or vial, 2, 3, 6 blister packs of 10 capsules, 1, 2, 4 blister packs of 14 capsules with the instructions for use are placed in a cardboard box.

Storage conditions:

In a dry, dark place, at a temperature not higher than 25 ° C.

Keep out of the reach of children.